Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 3/20 | 0.44 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6171168 | 0.88 | LMNA (0.53) | MMP13TP53 | |
| SCHEMBL6704533 | 0.83 | EPHX2 (0.53) | MMP13XDHAGTR1EGLN1TP53 | |
| SCHEMBL6703527 | 0.82 | MMP13 (0.39) | MMP13AGTR1AGTR2 | |
| SCHEMBL6167999 | 0.81 | EPHX2 (0.51) | MMP13XDHAGTR1EGLN1TP53 | |
| SCHEMBL6701090 | 0.81 | MMP13 (0.58) | MMP13XDHAGTR1TP53 | |
| SCHEMBL4102175 | 0.81 | PLA2G4A (0.53) | XDHAGTR1AGTR2 | |
| SCHEMBL4104344 | 0.80 | PLA2G4A (0.52) | XDHAGTR1AGTR2 | |
| SCHEMBL6167864 | 0.79 | MMP13 (0.75) | MMP13AGTR1AGTR2EGLN1 | |
| SCHEMBL6704526 | 0.79 | EPHX2 (0.47) | MMP13XDHAGTR1EGLN1 | |
| SCHEMBL6700187 | 0.78 | XDH (0.46) | MMP13XDHAGTR1EGLN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | claimed |
| EP-1530472-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | MMP13 2/4885XDH 242/4885AGTR1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.